Regencell Bioscience Leads Pharma Stocks in Year-to-Date Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Source: SeekingAlpha
S&P Healthcare Index Performance: The S&P healthcare index (XLV) achieved a year-to-date increase of 12.2% by mid-December 2025, ranking as the sixth-highest performing sector among the S&P 500 indexes.
Top Pharmaceutical Stocks: Regencell Bioscience (RGC) led the pharmaceutical sector with an extraordinary YTD performance of +15,138.46%, followed by Terns Pharmaceuticals (TERN) and Nuvation Bio (NUVB), which both received strong buy ratings.
Notable Stock Ratings: Nuvation Bio (NUVB) and Liquidia (LQDA) were highlighted for their strong buy ratings of 4.99 and 4.90, respectively, indicating strong investment potential.
Healthcare ETFs: Various healthcare ETFs, including XLV, VHT, and IHI, were mentioned as options for investors looking to gain exposure to the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: A class action lawsuit against LKQ alleges that from February 27, 2023, to July 23, 2025, executives failed to disclose significant risks regarding customer losses at FinishMaster, misleading investors and potentially harming the company's reputation and stock price.
- Regencell Bioscience Lawsuit: Regencell faces a class action from October 28, 2024, to October 31, 2025, accusing the company of not disclosing market manipulation risks and exposing investors to financial risks, which could lead to legal and reputational damage affecting future growth.
- Globant Lawsuit: A class action against Globant from February 15, 2024, to August 14, 2025, claims the company did not disclose declining demand in Latin America and wage freezes, misleading investors about the company's prospects and potentially impacting market performance.
- Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of the deadlines on June 22 and 23, 2026, encouraging them to participate in the lawsuits to protect their rights and ensure legal recourse.
See More
Regencell Bioscience Holdings Class Action Notice for Investors
- Class Action Notice: The Portnoy Law Firm advises investors of Regencell Bioscience Holdings (NASDAQ: RGC) about a class action for those who purchased securities between October 28, 2024, and October 31, 2025, with a deadline to file a lead plaintiff motion by June 23, 2026.
- Market Manipulation Risks: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny and enforcement actions.
- Expected Legal Costs: On October 31, 2025, Regencell disclosed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to market volatility, indicating that the company expects to incur significant legal costs and may face fines exceeding its insurance coverage.
- Stock Price Drop Impact: Following this news, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, reflecting market concerns about the company's future stability.
See More
Regencell Faces Shareholder Class Action Lawsuit
- Lawsuit Allegations: Regencell Bioscience Holdings Limited is facing allegations of making false and misleading statements regarding its business operations and compliance policies, which has left investors exposed to significant financial risks due to perceived market vulnerabilities.
- Market Volatility Impact: The resulting volatility in the market for Regencell's ordinary shares has led to substantial financial losses for investors, increasing the company's exposure to regulatory scrutiny and potential legal, monetary, and reputational harm.
- Investor Rights Protection: Investors who purchased Regencell shares between October 28, 2024, and October 31, 2025, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights and seek compensation for their losses.
- Legal Representation Credentials: Holzer & Holzer, established in 2000, has a strong track record in representing shareholders and investors in securities litigation, having recovered hundreds of millions of dollars for victims of fraud and corporate misconduct, underscoring their expertise and success in this field.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to potentially receive compensation without any out-of-pocket costs.
- Legal Risks Exposed: The lawsuit alleges that Regencell made false and misleading statements during the Class Period, exposing investors to market manipulation and significant financial risks, while increasing the company's vulnerability to regulatory scrutiny and legal liabilities.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Regencell Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose risks of market manipulation, which exposed investors to substantial financial losses and legal repercussions.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 23, 2026, highlighting the law firm's commitment to protecting investor rights while assuring that there are no upfront costs involved.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is a nationally recognized firm specializing in investor rights, having recovered hundreds of millions for investors, showcasing its expertise and successful track record in securities fraud class actions.
See More
Faruqi & Faruqi Investigates Regencell Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Regencell Bioscience Holdings Limited, urging investors who purchased securities between October 28, 2024, and October 31, 2025, to contact them before the June 23, 2026, deadline to seek lead plaintiff status.
- Market Manipulation Risks: The complaint alleges that Regencell and its executives violated federal securities laws by failing to disclose the company's vulnerability to market manipulation, exposing investors to significant financial risks and potential regulatory scrutiny, which could harm the company's reputation.
- Stock Price Plunge Impact: Following the October 31, 2025, disclosure of a subpoena from the U.S. Department of Justice, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share, resulting in substantial losses for investors.
- Investor Rights Protection: Faruq & Faruqi encourages investors who purchased Regencell securities during the Class Period to contact the firm to discuss their legal rights and participate in the class action lawsuit to seek compensation, ensuring that investors are adequately protected in the legal process.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: A class action lawsuit against LKQ alleges that from February 27, 2023, to July 23, 2025, executives failed to disclose significant risks regarding customer losses at FinishMaster, misleading investors and potentially harming the company's reputation and stock price.
- Regencell Bioscience Lawsuit: Regencell faces a class action from October 28, 2024, to October 31, 2025, accusing the company of not disclosing market manipulation risks and exposing investors to financial risks, which could lead to legal and reputational damage affecting future growth.
- Globant Lawsuit: A class action against Globant from February 15, 2024, to August 14, 2025, claims the company did not disclose declining demand in Latin America and wage freezes, misleading investors about the company's prospects and potentially impacting market performance.
- Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of the deadlines on June 22 and 23, 2026, encouraging them to participate in the lawsuits to protect their rights and ensure legal recourse.
See More
Regencell Bioscience Holdings Class Action Notice for Investors
- Class Action Notice: The Portnoy Law Firm advises investors of Regencell Bioscience Holdings (NASDAQ: RGC) about a class action for those who purchased securities between October 28, 2024, and October 31, 2025, with a deadline to file a lead plaintiff motion by June 23, 2026.
- Market Manipulation Risks: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny and enforcement actions.
- Expected Legal Costs: On October 31, 2025, Regencell disclosed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to market volatility, indicating that the company expects to incur significant legal costs and may face fines exceeding its insurance coverage.
- Stock Price Drop Impact: Following this news, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, reflecting market concerns about the company's future stability.
See More
Regencell Faces Shareholder Class Action Lawsuit
- Lawsuit Allegations: Regencell Bioscience Holdings Limited is facing allegations of making false and misleading statements regarding its business operations and compliance policies, which has left investors exposed to significant financial risks due to perceived market vulnerabilities.
- Market Volatility Impact: The resulting volatility in the market for Regencell's ordinary shares has led to substantial financial losses for investors, increasing the company's exposure to regulatory scrutiny and potential legal, monetary, and reputational harm.
- Investor Rights Protection: Investors who purchased Regencell shares between October 28, 2024, and October 31, 2025, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights and seek compensation for their losses.
- Legal Representation Credentials: Holzer & Holzer, established in 2000, has a strong track record in representing shareholders and investors in securities litigation, having recovered hundreds of millions of dollars for victims of fraud and corporate misconduct, underscoring their expertise and success in this field.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to potentially receive compensation without any out-of-pocket costs.
- Legal Risks Exposed: The lawsuit alleges that Regencell made false and misleading statements during the Class Period, exposing investors to market manipulation and significant financial risks, while increasing the company's vulnerability to regulatory scrutiny and legal liabilities.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Regencell Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose risks of market manipulation, which exposed investors to substantial financial losses and legal repercussions.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 23, 2026, highlighting the law firm's commitment to protecting investor rights while assuring that there are no upfront costs involved.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is a nationally recognized firm specializing in investor rights, having recovered hundreds of millions for investors, showcasing its expertise and successful track record in securities fraud class actions.
See More
Faruqi & Faruqi Investigates Regencell Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Regencell Bioscience Holdings Limited, urging investors who purchased securities between October 28, 2024, and October 31, 2025, to contact them before the June 23, 2026, deadline to seek lead plaintiff status.
- Market Manipulation Risks: The complaint alleges that Regencell and its executives violated federal securities laws by failing to disclose the company's vulnerability to market manipulation, exposing investors to significant financial risks and potential regulatory scrutiny, which could harm the company's reputation.
- Stock Price Plunge Impact: Following the October 31, 2025, disclosure of a subpoena from the U.S. Department of Justice, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share, resulting in substantial losses for investors.
- Investor Rights Protection: Faruq & Faruqi encourages investors who purchased Regencell securities during the Class Period to contact the firm to discuss their legal rights and participate in the class action lawsuit to seek compensation, ensuring that investors are adequately protected in the legal process.
See More
